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EDITORIAL
Best Practices for Clinical and Translational Research and
Implementation
DL Kroetz∗
Scientists in all sectors have been raising concerns in recent
years about the lack of reproducibility of biomedical research
results. An analysis of in-house validation efforts at Bayer
HealthCare found that <25% of potential targets could be
reproduced in-house.1 Similarly, of 53 “landmark” studies
selected because they described completely new findings,
only 11% could be confirmed in-house by Amgen scientists.2
Such dismal numbers have raised concern among scientists
in all sectors about the lack of transparency in reporting sci-
entific results and the need to share best laboratory and clin-
ical practices. In response, more training in rigor and repro-
ducibility, study design, and statistical analysis has been
mandated by the National Institutes of Health.3 A NINDS task
force was one of the first to call on journals to play a more
important role in improving the impact of basic and transla-
tional research by requiring higher standards of evidence and
access to detailed methods, code, and data for publication.4
In a climate where increasing research costs and reduced
funding have changed the landscape of academic and pri-
vate sector research, it is even more critical that all research
is performed at the highest possible standards. Similarly,
drug development costs continue to rise and a high level of
scrutiny is given to the design and interpretation of preclinical
and clinical studies in the pharmaceutical and biotechnology
industries.
The major factors underlying deficiencies in scientific rigor
and reproducibility are gaps in training and the absence of
widely available best practices. The fields of clinical and
translational science are no exception. Clinical and transla-
tional research requires an interdisciplinary team of investi-
gators. Clinicians and researchers with training in medicine,
pharmacy, pharmacology, pharmaceutical sciences, and
bioinformatics bring a diversity of skills and knowledge to
the table; this presents both opportunities and challenges.
While the breadth of training is critical for the interdis-
ciplinary nature of translational research and medicine,
the specialized training in most fields limits the tools and
knowledge available to an individual researcher. To address
this need, Clinical and Translational Science is launching a
tutorial section. Focusing on important and timely topics of
relevance to the broad field of clinical pharmacology and
translational medicine, tutorials will provide practical advice
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and nuanced perspectives from leaders in the field. The goal
is to address the need for best practices, highlight chal-
lenges and opportunities for improvement, and to develop
a sense of community that is driven by a common goal of
improved patient outcomes with more effective and safer
medications.
The inaugural tutorial by Arwood et al. provides a detailed
framework for implementing pharmacogenetic testing in the
clinic. President Obama highlighted the promise of optimized
drug therapy in his 2015 State of the Union address and
several projects in the Implementing Genomics in Practice
(IGNITE) network funded by the National Human Genome
Research Institute focus on pharmacogenomic markers.
The Pharmacogenomics Research Network funded by the
National Institute of General Medical Sciences supported
many critical discovery studies that form the basis for several
clinically actionable gene–drug associations. After decades
of intensive pharmacogenomics discovery research, the time
is ripe for translating these findings into the clinic. While
widely supported in theory, implementation of pharmaco-
genetics has been slow. Few clinicians (and even fewer
researchers) have the knowledge and training to implement
new clinical practices. Implementation to date has been
achieved by a lengthy process of trial and error and the devel-
opment of numerous new tools and standards. Luckily for
those who will lead efforts in their own institutions to imple-
ment pharmacogenetic testing, the pioneers have carefully
documented their path from concept to implementation and
generously shared these experiences with the larger com-
munity. The pharmacogenetic implementation tutorial in this
issue addresses the entire process from selection of gene–
drug pairs to outcome analysis in an easy to understand
manner.
A regular series of tutorials is planned that will embrace
the spirit of education and cooperation that is critical for
rigorous scientific research and translation of findings to
benefit society. Upcoming topics will consider the use of
next generation sequencing in clinical trials, selection of
first in human dose, and the development of complemen-
tary or companion diagnostics. We welcome your sug-
gestions on topics of interest to clinical and translational
scientists.
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